Table 3. The predicted synthetic lethal pairs which had (putative) synergistic correlation when tested against five clinical features, where the synergistic correlation was conducted by multiple Fisher's tests; the false positive rate (FDR) was estimated by q-value.

Protein1	Protein2	p-value			FDR	Log-rank testa (p-value)
		Protein1	Protein2	Protein Pairs
A. Overall Survival
FEN1(N)	RAD54B(N)	0.357	0.002	0.001	0.126	0.000
BRCA1(C)	RAD54B(N)	0.442	0.002	0.001	0.126	0.000
PARP1(N)	RAD54B(N)	0.252	0.002	0.002	0.162	0.000
BRCA1(C)	FEN1(N)	0.442	0.357	0.016	0.356	0.056
B. Metastasis
CSNK1E(C)	TP53(N)	0.682	0.012	0.003	0.369	0.420
BRCA1(C)	TP53(N)	0.281	0.012	0.005	0.369	0.129
POLB(N)	TP53(N)	0.485	0.012	0.007	0.369	0.108
PARP1(N)	TP53(N)	0.299	0.012	0.008	0.369	0.414
RB1(N)	TP53(N)	0.114	0.012	0.008	0.369	0.092
BRCA1(C)	RB1(N)	0.281	0.114	0.037	0.897	0.756
C. Lymph node Metastasis
CDH1(M)	MSH2(C)	0.472	0.084	0.007	0.973	0.280
BRCA2(C)	MSH2(C)	0.245	0.084	0.016	0.973	0.520
FEN1(N)	MSH2(C)	0.212	0.084	0.022	0.973	0.502
BRCA1(C)	EGFR(C)	0.355	0.103	0.033	0.973	0.857
BRCA2(N)	TP53(N)	0.190	0.351	0.045	0.973	0.483
MSH2(C)	RB1(N)	0.084	0.220	0.045	0.973	0.306
D. Grade
ABL1(C)	CTNNB1(N)	0.781	0.169	0.021	0.931	0.842
ARK2(C)	BRCA2(N)	0.380	0.108	0.031	0.931	0.720
BRCA2(N)	POLB(N)	0.108	0.384	0.039	0.931	0.985
MSH2(C)	MYC(N)	0.058	0.448	0.047	0.931	0.347
BRCA1(C)	BRCA2(N)	0.407	0.108	0.049	0.931	0.338
E. Stage
CDH1(M)	RB1(N)	0.346	0.107	0.012	0.974	0.632
EGFR(C)	RB1(N)	0.268	0.107	0.031	0.974	0.882
FEN1(N)	MSH2(C)	0.538	0.395	0.033	0.974	0.502
BRCA1(C)	TP53(N)	0.217	0.144	0.038	0.974	0.129
PARP1(N)	RB1(N)	0.381	0.107	0.048	0.974	0.234

^aFor each of those pairs with P < 0.05, the survival curve of LADC patients with both proteins abnormally expressed is separated from that of the remaining group.

Those marked in yellow were predicted by the original synergistic correlation, while the remaining ones by the putative synergistic effect.